Reich, K ; Papp, K ; Armstrong, W... Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen YK, Li S, Kibmall AB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017 Mar;76(3):405-17. DOI:10.1016/j.jaad.2016.11.041.
,
2018
